Elevated MICs of susceptible antipseudomonal cephalosporins in non-carbapenemase-producing, carbapenem-resistant pseudomonas aeruginosa: Implications for dose optimization

Gill, Christian; Aktaş, Elif; Alfouzan, Wadha; Bourassa, Lori; Brink, Adrian; Burnham, Carey-Ann; Canton, Rafael; Carmeli, Yehuda; Falcone, Marco; Kiffer, Carlos; Marchese, Anna; Martinez, Octavio; Pournaras, Spyros; Seifert, Harald; Thabit, Abrar; Villegas, Maria; Westblade, Lars; Nicolau, David; Wille, Julia; Rezende, Thais; Cekin, Zuhal; Malkocoglu, Gulsah; Gijón, Desirèe; Tarakmeh, Layla; Chu, Chun; Opperman, Christoffel; Tootla, Hafsah; Moodley, Clinton; Coetzee, Jennifer; Vourli, Sophia; Dimopoulos, George; Attallah, Dalya; Tiseo, Giusy; Leonildi, Alessandro; Giordano, Cesira; Barnini, Simona; Menichetti, Francesco; Di Pilato, Vincenzo; Codda, Giulia; Vena, Antonio; Giacobbe, Daniele; Satlin, Michael; Cardona, Armando; Curtis, Lauren; Fang, Ferric; Thomson, Gina; Thomson, Ken

doi:10.1128/aac.01204-21

Elevated MICs of susceptible antipseudomonal cephalosporins in non-carbapenemase-producing, carbapenem-resistant pseudomonas aeruginosa: Implications for dose optimization

Gill C. M., Aktaş E., Alfouzan W., Bourassa L., Brink A., Burnham C. D., ...Daha Fazla

Antimicrobial Agents and Chemotherapy, cilt.65, sa.11, 2021 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 65 Sayı: 11
Basım Tarihi: 2021
Doi Numarası: 10.1128/aac.01204-21
Dergi Adı: Antimicrobial Agents and Chemotherapy
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, Chimica, EMBASE, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database, DIALNET
Anahtar Kelimeler: Pseudomonas aeruginosa, carbapenem resistance, cefepime, ceftazidime, pharmacodynamics, pharmacokinetics
Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

The present study evaluated the in vitro potency of ceftazidime and cefepime among carbapenem-resistant Pseudomonas aeruginosa isolates collected as part of a global surveillance program and assessed the pharmacodynamic implications using previously published population pharmacokinetics. When susceptible, MICs resulted at the high end of distribution for both ceftazidime and cefepime, thus 6 g/day was required to achieve optimal pharmacodynamic profiles. These findings should be considered in the clinic and for the application of CLSI susceptibility breakpoints.